Aktis Oncology, Inc. (AKTS) vs Monte Rosa Therapeutics, Inc. (GLUE)
A side-by-side comparison of Aktis Oncology, Inc. and Monte Rosa Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.64HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
GLUE
Monte Rosa Therapeutics, Inc.
$10.27HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AKTS vs GLUE
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)GLUE -59.4% (-59.4%/yr)AKTS compounded faster over this window
AKTS GLUE
AKTS vs GLUE: by the numbers
- •AKTS is the larger company ($995M vs $868M market cap).
- •Both run net losses; GLUE's is the smaller (-560.85% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | GLUE |
|---|---|---|
| P/S ratio | 98.95 | 30.20 |
| P/B ratio | 2.05 | 1.78 |
Profitability
| Metric | AKTS | GLUE |
|---|---|---|
| Gross margin | 100.00% | 92.94% |
| Operating margin | -1149.52% | -43.83% |
| Net margin | -727.04% | -560.85% |
| ROE | -15.09% | -33.06% |
| ROIC | -16.54% | -28.69% |
Growth (annualized)
| Metric | AKTS | GLUE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -12.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.